166 0 Kommentare 22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and Policy Conference - Seite 2

Panelists will examine the public health impact of regulating nicotine content across the broad spectrum of tobacco and nicotine products; the ways in which policies can help minimize users' health risks; and the mitigation of potential unintended consequences. Pritchard will also discuss 22nd Century’s role in ensuring the adoption of the FDA’s proposed reduced nicotine product standard, requiring all cigarettes sold in the U.S. to be “minimally... or non-addictive.” 22nd Century is committed to making reduced nicotine technology available to the entire tobacco industry. Licensing the Company’s reduced nicotine technology to tobacco companies will allow the industry to deliver on their commitments to reduce combustible cigarette consumption and to comply with the FDA’s reduced nicotine standard.

22nd Century believes that the FDA is in the final stages of its decision-making process for the Company’s Modified Risk Tobacco Product (MRTP) Applications for VLN. An authorization decision by the FDA will bring to market the first and only combustible cigarettes available with 95% less nicotine compared to other cigarettes, further demonstrating the technical feasibility of the FDA’s generationally significant product standard.

Pritchard’s presentation will be accessible in the Investors section of 22nd Century’s website, under Events.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (NYSE American: XXII) is a leading, plant-based, life science company that develops and provides disruptive, commercial solutions to the life science, consumer products, and pharmaceutical markets. Working with tobacco and hemp/cannabis plants, 22nd Century is dedicated to its mission of reducing the harm caused by smoking. The Company’s proprietary reduced nicotine VLN cigarettes contain 95% less nicotine than conventional brands and are poised to disrupt the more than $800 billion global tobacco market. 22nd Century owns or controls more than 200 issued and pending patents related to the tobacco and hemp/cannabis plants.

Learn more at xxiicentury.com, on Twitter @_xxiicentury and on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in our Annual Report on Form 10-K filed on March 11, 2020 and in our subsequently filed Quarterly Report on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events, or otherwise, except as otherwise required by law.

All information provided in this release is as of the date hereof, and we assume no obligation to and do not intend to update these forward-looking statements, except as required by law.